Viking Therapeutics (VKTX) is emerging as a prime acquisition target in the biotech sector, driven by its promising obesity drug candidate, VK2735, which is advancing through Phase 3 trials. The company’s dual formulation—both injectable and oral—positions it strategically as major pharmaceutical firms scramble to secure obesity drug assets amid a burgeoning market projected to exceed $100 billion annually. Recent Phase 2 results indicate significant weight loss, bolstering Viking’s appeal as it navigates a landscape with limited late-stage competitors.

The urgency for large pharma to acquire effective obesity therapies is underscored by the success of existing products like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, which have already generated substantial revenues. With Viking’s market capitalization currently around $30 per share—well below analyst price targets of $95—investors see a compelling opportunity if VK2735 continues to demonstrate strong efficacy.

For market professionals, the key takeaway is that Viking’s robust pipeline, financial stability, and strategic positioning make it a noteworthy player in the ongoing consolidation of the obesity drug market, presenting potential upside for investors as acquisition discussions heat up.

Source: fool.com